Abe’s presentation, titled The Longevity Opportunity in Asia: Building the Infrastructure for an Aging World, positions Japan as a critical laboratory for the global market. Given the nation’s unique demographic landscape, international investors increasingly view Japan as a primary site for testing longevity strategies and validating scientific research. Abe Yoando Pharma, which traces its lineage to 1731 as physicians to the Matsudaira clan, currently represents Japan as one of the 20 finalists in the global XPRIZE Healthspan competition.
In section Releases
Abe Yoando Pharma President to Address Longevity Investors Conference
Tomonari Abe, president of the 295-year-old Abe Yoando Pharma, will become the first Japanese speaker to take the stage at the Longevity Investors Conference in Gstaad, Switzerland. Running from September 14 to 17, 2026, the event highlights Asia’s growing influence in a sector projected to reach $8 trillion by 2030.
At the conference, the company intends to showcase its dual-pronged approach: blending historical wellness traditions with modern biotechnology. The firm is currently focused on the development of high-purity nicotinamide mononucleotide (NMN) and ongoing joint studies regarding sirtuin genes. By leveraging these ancient insights alongside contemporary clinical inquiry, Abe plans to present a blueprint for scalable longevity infrastructure that can be exported from Asia to serve an aging world.
Comments (0)
No comments yet. Be the first!